After Germany revamped its approach to purchasing medicines a decade ago, the prices negotiated by the government for cancer treatments were more closely aligned with clinical benefits, a new study finds. Moreover, the effort led to a 25% drop in prices one year after product launches, prompting the researchers to suggest U.S. policymakers should consider Germany as a cost-saving model.

In reaching their conclusion, the researchers examined data for 57 cancer treatments that were launched in Germany from 2002 to 2017. Specifically, they compared incremental health benefits and costs of these treatments before and after the country enacted a law in 2011 which allowed drug makers to freely set prices for newly authorized medicines for one year before negotiations take place.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Capitalism harnesses the animal instincts to produce good things. Capitalism is not about greed. It is a system that weeds out dumb ideas from smart ones.

    The former generate disdain and losses; the latter generate delight and profits and, dare I say, lifesaving drugs.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy